Complete Genomics Introduces Mpox Virus Sequencing Panel
Complete Genomics, a leading genomic sequencer manufacturer based in San Jose, Calif., has made a significant announcement at a recent Annual Meeting & Expo event. The company introduced a novel mpox (MPXV) virus amplicon sequencing panel, which is a vital addition to its existing sequencing product range tailored for pathogenic microorganisms.
Understanding the Mpox Virus Strains
In recent years, the emergence of new mpox virus strains has raised public health concerns worldwide. The virus, existing in two main clades—clade I and clade II—has been particularly noteworthy due to the global outbreak witnessed in 2022, predominantly driven by clade II. Currently, a novel strain from the Ib clade has been reported to spread across various regions, highlighting the need for precise and advanced monitoring.
Global Impact and Case Reports
As highlighted in recent health reports, an alarming total of 115,000 mpox cases, encompassing both clade I and clade II, have been documented across 123 countries this year. Public health officials have recently confirmed the identification of a strain that was previously undetected in the U.S., tied to an individual who traveled back from Eastern Africa. Fortunately, state health officials in California have reported no evidence of further transmission in this case.
The Importance of High-Quality Sequencing Products
Rob Tarbox, VP of Product and Marketing at Complete Genomics, emphasized the significance of accessible, high-quality sequencing products for researchers globally. He stated, “The new strain of the mpox virus demonstrates why it is crucial to public health that researchers worldwide, including those in the U.S., have access to affordable and high-quality sequencing products.” This statement highlights the urgency for innovation in genome sequencing to effectively monitor and combat emerging viral strains.
Features of the New Sequencing Panel
The newly launched mpox virus amplicon sequencing panel employs ATOPlex multiplex PCR technology. It has been seamlessly integrated with proprietary reagents, instruments, and software, which enables comprehensive coverage of the virus’s full-length genome. This facilitates rapid identification, traceability, and quantification of the viral load. Additionally, the advanced MPXV analysis software aids in virus identification, mutation detection, and strain typing, ensuring that researchers have the tools necessary for precise and accurate genomic analysis.
Complete Genomics in the Global Context
In a pursuit to expand its portfolio, Complete Genomics has also introduced a complete next-generation sequencing (NGS) solution targeting the Dengue virus (DENV), a prevalent cause of dengue fever. This solution encompasses the entire process from sample extraction to library preparation based on ATOPlex amplicon technology, alongside DNBSEQ sequencing and subsequent data analysis.
About Complete Genomics
Established in 2005, Complete Genomics is a pioneering leader in the life sciences domain. The company specializes in delivering innovative, end-to-end DNA sequencing solutions. Its commitment to advancing high-throughput cost-effective sequencing technology has borne fruit, empowering over 9,400 publications across numerous applications. To explore more, interested parties can visit the company's website.
* For Research Use Only. Not for use in diagnostic procedures.
Frequently Asked Questions
What is the mpox virus amplicon sequencing panel?
The mpox virus amplicon sequencing panel is a targeted sequencing product designed to identify and monitor mpox virus strains using advanced multiplex PCR technology.
Why is this sequencing panel important?
This panel allows researchers to efficiently identify and track new mpox strains, which is crucial for public health amidst rising global cases of the virus.
How does the panel enhance public health research?
By providing rapid and accurate sequencing capabilities, the panel helps researchers and health officials respond more effectively to mpox outbreaks and identify viral mutations.
What additional solutions did Complete Genomics launch?
They have launched an end-to-end NGS solution for the Dengue virus, which includes comprehensive capabilities from sample extraction through data analysis.
When was Complete Genomics established?
Complete Genomics was founded in 2005 and has been at the forefront of genomic sequencing technologies since then.
